^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
dociparstat sodium (CX-01)
i
Other names: CX-01, PGX-100, ODSH, PGX-ODSH-2013-AML-1, PGX 100, DSTAT
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Cantex Pharma, Chimerix
Drug class:
CXCL12 inhibitor, CXCR4 antagonist, Cathepsin G inhibitor, HMGB1 inhibitor, Human leukocyte elastase inhibitor, P selectin inhibitor
Related drugs:
8ms
Dociparstat in Combination With Standard Chemotherapy for the Treatment of Acute Myeloid Leukemia (clinicaltrials.gov)
P3, N=9, Terminated, Chimerix | Active, not recruiting --> Terminated; Study enrollment was terminated on 16 May 2022 due to slow recruitment.
Trial termination • Combination therapy
|
dociparstat sodium (CX-01)
3years
Combination of dociparstat sodium (DSTAT), a CXCL12/CXCR4 inhibitor, with azacitidine for the treatment of hypomethylating agent refractory AML and MDS. (PubMed, Leuk Res)
While cytopenias and infections were common, these were not out of proportion to what would be expected in this population of patients undergoing treatment with azacitidine alone. In summary, this trial demonstrated the feasibility of combining DSTAT with azacitidine, with several responses observed, suggesting this combination warrants further study.
Journal
|
CXCR4 (Chemokine (C-X-C motif) receptor 4) • CXCL12 (C-X-C Motif Chemokine Ligand 12) • HMGB1 (High Mobility Group Box 1)
|
azacitidine • dociparstat sodium (CX-01)
Share via
